Selective compensatory induction of hepatic HMG-CoA reductase in response to inhibition of cholesterol absorption.
The effect of the potent inhibitor of cholesterol absorption, ezetimibe, on serum cholesterol levels was tested in diabetic and thyroidectomized male Sprague-Dawley rats. Feeding diets supplemented with 1% cholesterol to the diabetic rats raised serum cholesterol levels from 132 to 514 mg/dl while decreasing hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase protein and mRNA levels. Addition of 10 mg/kg/day of ezetimibe to the diets of these animals lowered the serum cholesterol level to 90 mg/dl and produced a large compensatory increase in hepatic HMG-CoA reductase protein without significantly increasing mRNA levels, indicating a post-transcriptional effect. Hepatic LDL receptor protein levels in these diabetic rats were unaffected by ezetimibe treatment. In contrast, ezetimibe treatment of these young normal Sprague-Dawley rats, known to express high levels of hepatic HMG-CoA reductase, did not lower serum cholesterol levels. In thyroidectomized rats, dietary cholesterol increased serum cholesterol levels from 116 to 135 mg/dl and ezetimibe treatment lowered these elevated cholesterol levels to 85 mg/dl. Cholesterol feeding of thyroidectomized rats severely reduced hepatic HMG-CoA reductase protein, while ezetimibe treatment restored reductase protein to normal levels. Again, hepatic LDL receptor protein levels were unaffected by ezetimibe treatment of cholesterol-fed thyroidectomized rats. The data demonstrate that the cholesterol absorption inhibitor ezetimibe profoundly lowers serum cholesterol levels in animals expressing very low rates of hepatic cholesterol synthesis and produces large compensatory increases in hepatic HMG-CoA reductase expression without significantly affecting expression of hepatic LDL receptors. This indicates that ezetimibe should be most effective in lowering serum cholesterol levels in people with low rates of cholesterol synthesis/high rates of cholesterol absorption.
Ness
Gene C
GC
Department of Biochemistry and Molecular Biology, College of Medicine, 12901 Bruce B. Downs Boulevard, University of South Florida, Tampa, FL 33612, USA. gness@hsc.usf.edu
Holland
Reed C
RC
Lopez
Dayami
D
D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D002784:Cholesterol / Q000378:metabolism*; D002791:Cholesterol, Dietary; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D004790:Enzyme Induction; D000069438:Ezetimibe; D006903:Hydroxymethylglutaryl CoA Reductases / Q000235:genetics / Q000378:metabolism*; D006937:Hypercholesterolemia / Q000188:drug therapy; D008099:Liver / Q000201:enzymology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011973:Receptors, LDL / Q000235:genetics / Q000378:metabolism; D013963:Thyroid Hormones / Q000097:blood; D013965:Thyroidectomy; D014158:Transcription, Genetic
D000924:Anticholesteremic Agents; D001384:Azetidines; D002791:Cholesterol, Dietary; D011973:Receptors, LDL; D013963:Thyroid Hormones; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases; D000069438:Ezetimibe